BeyondSpring, Inc. · NASDAQ:BYSI
BeyondSpring — Investor Presentation (September 2021)
52 slides from BeyondSpring's investor presentation, September 2021
Slide 1: Corporate Presentation
Corporate Presentation September 2021 | NASDAQ: BYSI 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared for informational purposes only. No money or other consideration is being solicited, and if sent in response, will not be accepted. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shal
Slide 3: Investment Highlights (NASDAQ Ticker – BYSI)
Investment Highlights (NASDAQ Ticker – BYSI) Headquarter New York, NY Plinabulin for CIN, US NDA PDUFA November 30, 2021 Committed to raising the standard Lead Asset Plinabulin for NSCLC, est. NDA filing 1H 2022 of care for cancer patients with first- in-class treatments that improve Partnerships: P
Slide 4: Two Near-Term NDAs & Robust Drug Development Pipeline
Two Near-Term NDAs & Robust Drug Development Pipeline Indication / Trial Name / Commercial Program Preclinical Phase 1 Phase 2 Phase 3 Status/Next Milestone Target Collaborator Rights1 • U.S. and China NDA accepted with Priority CIN Review; US PDUFA Nov. 30, 2021 PROTECTIVE-1 Phase 3 primary endpoin
Slide 5: Plinabulin Franchise: Pipeline in a Drug
Plinabulin Franchise: Pipeline in a Drug Clinical Confirmation Expand Transform Promising early clinical efficacy data Positive Phase 3 Topline OS data (n=559) – 7 different cancers in phase 1/2 study & potential NDA filing 1H 2022 Confirmed in 6 clinical studies (n>1200) & Filed for NDA approval CI
Slide 6: Plinabulin: Pipeline in a Drug - First-in-Class SIMBA
Plinabulin: “Pipeline in a Drug” - First-in-Class, Selective Immunomodulating Microtubule- Binding Agent (SIMBA) 6
Slide 7: Plinabulin: First-in-Class SIMBA - Potent APC Inducer
Plinabulin: First-in-Class, Selective Immunomodulating Microtubule- Binding Agent (SIMBA) - Potent Antigen Presenting Cell (APC) Inducer GEF-H1 activation2 1 Plinabulin Rho/ROCK activation1 Microtubules Neutrophil demargination7 Kill cancer cells4 JNK activation2 Dendritic cell maturation2,3 Kill ca
Slide 8: Plinabulin Induces Dendritic Cell Maturation
Plinabulin Induces Dendritic Cell Maturation (the most potent APC), a Key Step in Initiating Anti-cancer Durable Response ❷ Plinabulin 2 3 ❸ Checkpoint Inhibitors Stimulate maturation of dendritic Optimize T cell response cells to increase antigen presentation Dendritic cells are the most important
Slide 9: Triple I/O Combo: Plinabulin + PD-1 + Radiation
Triple I/O Combo: Plinabulin + PD-1 + Radiation (IR), Best Tumor Response in PD-1 Non-Responsive Tumor Model (MD Anderson) Tumor Volume (mm3) 2000 1000 0 DC activation is most dramatic in triple T cell doubles in triple I/O Combination I/O combination vs. PD1 + IR Biomarker data in tumor 30 days aft
Slide 10: Plinabulin Clinical Development Program
NB Plinabulin Clinical Development Program SS DI A Q Study 101 Phase 1/2 Phase 2 Efficacy Data Phase 2 Phase 3 Registration Protective-1: Plinabulin vs. Pegfilgrastim Study 105 (PROTECTIVE-1) Study 105 (PROTECTIVE-1) Plinabulin (various dose) vs. Plinabulin vs. Pegfilgrastim (n=105) Pegfilgrastim (n
Slide 11: Delivering the Plinabulin Value Proposition
Delivering the Plinabulin Value Proposition CIN ANTI-CANCER ANTI-CANCER Near-Term w/ Chemotherapy w/ Immuno-Oncology Market Opportunity Raise the Improve Survival and Potential Standard of Care Quality of Life APC Cornerstone of emerging regimens 11
Slide 12: Severe Unmet Medical Need for Plinabulin + G-CSF in CIN Prevention
Severe Unmet Medical Need is Basis for Breakthrough Designation and Priority Review for Plinabulin + G-CSF Regimen in CIN Prevention Despite widespread G-CSF use, CIN #1 reason for FN, ER visits, hospitalization, sepsis, mortality, and chemotherapy disruption1 Short-term Outcome Benefit Long-term Ou
Slide 13: Plinabulin + G-CSF Combination Addresses Unmet Medical Need
Plinabulin + G-CSF Combination Addresses Unmet Medical Need Plinabulin is the only product – in development – that has demonstrated the potential to elevate the standard of care (SOC) to prevent CIN 7.0 Neulasta 6 mg (n=22) • Breakthrough Therapy Designation: Unmet Plinabulin 20 mg/m2 + Neulasta 6 m
Slide 14: Protective-2 (Study 106) Ph 3: Registration Study Design
Protective-2 (Study 106) Ph 3: Registration Study Design • Double blind, global study (19 centers); 4 cycles • Covance: CRO • Covance central lab: ANC evaluation Plinabulin 40mg + Pegfilgrastim 6 mg N=111 Breast Cancer, R 1:1 TAC Therapy Placebo + Pegfilgrastim 6 mg N=110 14
Slide 15: PROTECTIVE-2 Ph3: Primary Endpoint Met
PROTECTIVE-2 Ph3: Primary Endpoint Met Proportion of Patients with No Grade 4 Neutropenia (or DSN= 0 Days) in Cycle 1 35% 31.5% 30% p-value=0.0015 25% Patients 20% (%) 15% 13.6% 10% 5% N=110 N=111 0% Pegfilgrastim 6 mg Plinabulin 40 mg + Pegfilgrastim 6 mg • Grade 4 neutropenia (ANC < 0.5 x 109 cell
Slide 16: Favorable Benefit/Risk Ratio (Plinabulin + G-CSF vs. G-CSF alone)
Favorable Benefit/Risk Ratio (Plinabulin + G-CSF vs. G-CSF alone) Improved Efficacy (ANC based Improved Efficacy (FN) Favorable Safety in Cycle 1) – 106 Phase 3 – 106 Phase 3 – 106 Phase 2+3 No Grade 4 Neutropenia FN Grade 4 TEAE (primary endpoint) • 3.6% vs. 6.3% (incidence) • 20% less Grade 4 TEAE
Slide 17: NDA accepted with Priority review by US and China FDA
NDA accepted with Priority review by US and China FDA (US PDUFA 11/30/2021) Seeking NDA Approval for “Plinabulin + G-CSF Combination” in a broad CIN Prevention label: all solid tumor, all chemotherapy Registration Study Supporting Studies Supporting Studies Plinabulin + G-CSF combo Plinabulin vs. pl
Slide 18: Plinabulin + G-CSF Combination - Commercial Plan in CIN Prevention
Plinabulin + G-CSF Combination - Commercial Plan in CIN Prevention 18
Slide 19: Chemotherapy Without Compromise: Turning the Ds into the Ss
Chemotherapy Without Compromise: Turning the 4 Ds into the 4 Ss DECREASED STABLE DOSE recommended dose maintaining >85% Plinabulin + G-CSF DELAYED cycles SUSTAINED CYCLES cycles on time • Differentiated clinical profile, potential to improve SOC DISCONTINUED chemotherapy STAY THE COURSE complete all
Slide 20: CIN Prevention: Near-term Large Market Potential
CIN Prevention: Near-term Large Market Potential - With PD-1 and chemo combination approved, “chemo is here to stay” Plinabulin could potentially be used with each cycle of G-CSF in solid tumors for improved protection US Market: NCCN Guidelines Doubled Market for CIN Chemotherapy remains 650,000 US
Slide 21: Plinabulin: Potential for Use Across the Spectrum of Solid Tumors
Plinabulin: Potential for Use Across the Spectrum of Solid Tumors G-CSF Administrations: Solid Tumor Rectal Cancer Gynecological 5% Cancer, Other G-CSF use by cancer type: Ovarian 5% Cancer • Improved control of CIN with 5% Plinabulin can prove important in Prostate Cancer cancers with more aggressi
Slide 22: Prioritize on Large and Rapid Adopters at Launch
Prioritize on Large and Rapid Adopters at Launch Pegfilgrastim Patient Distribution1 – Top 1200 Centers US Regional Coverage Top 3 deciles = 81% 99% 100% 98% 100,000 of pts (~360 accts) 94% 96% 100% 91% 90,000 87% 90% 85,879 81% 80,000 80% 72% Cumulative Contribution (%) 70,000 70% G-CSF concentrati
Slide 23: Targeted Commercialization Plan
Targeted Commercialization Plan Drive awareness of the "Neutropenia FOCUS: Elevating the SOC in chemotherapy 01 Vulnerability Gap” and unmet need Position Plinabulin with key decision 02 makers Key Account Neutropenia Plinabulin Activation Vulnerability Positioning /Access & Gap Availability Activat
Slide 24: Breakthrough Therapy Designation with FDA NDA Priority Review
Breakthrough Therapy Designation with FDA NDA Priority Review: Potential to Elevate SOC for CIN Prevention Opportunity Unmet need Product differentiation ✓Market size ✓Grade 4 neutropenia complications Plinabulin + G-CSF addresses 3 oncologist ✓Market growth ✓CIN: #1 reason for therapy change needs:
Slide 25: Delivering the Plinabulin Value Proposition
Delivering the Plinabulin Value Proposition CIN ANTI-CANCER ANTI-CANCER NEAR-TERM w/ Chemotherapy w/ Immuno-Oncology Market Opportunity Raise the Improve Survival and Potential Standard of Care Quality of Life APC Cornerstone of emerging regimens 25
Slide 26: Severely Unmet Medical Need – 2nd/3rd Line NSCLC, EGFR Wild Type
Severely Unmet Medical Need – 2nd/3rd Line NSCLC, EGFR Wild Type • Large patient population with limited Efficacy treatment options o EGFR wild type: ~85% western NSCLC and ~70% of Asian NSCLC patients Safety o With immunotherapies moved to first line, Docetaxel-based therapies are the mainstay ther
Slide 27: Underserved Market: 2nd/3rd Line NSCLC Treatment
Underserved Market: 2nd/3rd Line NSCLC Treatment With PD-1/PD-L1 Moved To First Line, Patients are Left with Efficacy and Safety Tradeoffs and Suboptimal Regimens Treatment Ramuciramab + Docetaxel vs. Docetaxel1 Pemetrexed vs Docetaxel2 Pros Limited efficacy; OS HR: 0.86 Low CIN risk Low Efficacy, O
Slide 28: Scientific Rationale – Patients with High GEF-H1 Live Longer
Scientific Rationale – Patients with High GEF-H1 Live Longer Plinabulin Activates GEF-H11 Patients with High GEF-H1 Immune Signature Live Longer in Various Cancers1 Based on Plinabulin’s Immune MOA, patients with measurable lung lesion were selected prospectively for Dublin-3 Study. 1 Kashyap et al.
Slide 29: Docetaxel + Plinabulin vs Docetaxel + Placebo in 2nd/3rd line NSCLC (DUBLIN-3)
Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With 2nd/3rd line NSCLC, EGFR wild type (DUBLIN-3) Global, Randomized, Single-Blinded (blinding for patients only) Stratified for: Region (Asia/non-Asia), Prior Line, ECOG score Around 60 sites: U.S., China, and Australia Docetaxel C
Slide 30: Dublin-3 Phase 3 Topline Data
Dublin-3 Phase 3 Topline Data - Significant Improvement in OS, PFS, ORR, 24 M, 36 M OS Rate (Combo vs. Docetaxel) - Significant Reduction in Grade 4 Neutropenia (Combo vs. Docetaxel) Plinabulin (30 mg/m2) Docetaxel (75 mg/m2) + Docetaxel (75 mg/m2) Primary Endpoint N=281 N=278 Mean OS, p=0.03 OS (mo
Slide 31: Product Profile (Plinabulin + Docetaxel for 2nd/3rd line NSCLC)
Product Profile (Plinabulin + Docetaxel for 2nd/3rd line NSCLC, EGFR wild type) Next steps: Discuss filing plan with FDA & NMPA in 2021 with potential filing 1H 2022 Docetaxel (Current SOC) Plinabulin - Docetaxel Combination • Survival benefit, with longer survival • Modest survival benefit due to G
Slide 32: Delivering the Plinabulin Value Proposition
Delivering the Plinabulin Value Proposition CIN ANTI-CANCER ANTI-CANCER NEAR-TERM w/ Chemotherapy w/ Immuno-Oncology Market Opportunity Raise the Improve Survival and Potential Standard of Care Quality of Life APC Cornerstone of emerging regimens 32
Slide 33: Plinabulin: Potential as the Cornerstone Therapy to Add onto Current IO Therapies
Plinabulin: potential as the “Cornerstone” Therapy to Add onto Current IO Therapies to Address Severe Unmet Medical Needs PD-1/PD-L1 Inhibitors Potential to greatly expand - $30B global annual sales the addressable market Current Severe Unmet Medical Needs Plinabulin Clinical Development • PD-1/PD-L
Slide 34: Triple I/O Combo Development for Multiple Cancer Indications
Triple I/O Combo Development for Multiple Cancer Indications in PD- 1/PD-L1 Failed Patients – Severe Unmet Medical Needs Trial Name / Indication / Target Program Commercial Rights Status Collaborator SCLC Plinabulin + 7 US sites, including Phase 1 completed, Checkpoint naïve and Nivolumab (PD-1) + R
Slide 35: Plinabulin + Nivolumab + Ipilimumab in SCLC: Study Design
Plinabulin+ Nivolumab +Ipilimumab in SCLC: Study Design Dose-escalation phase I study 3+3 Design ▪ In patients with extensive-stage SCLC who had progressed on or after prior platinum-based chemotherapy (±PD-1/PD-L1) Primary objective ▪ To determine dose-limiting toxicities (DLT’s) and recommended Ph
Slide 36: Efficacy Analysis
Efficacy Analysis Data cutoff –December 30,2020 PD-1/PD-L1 PD-1/PD-L1 resistant Efficacy Analysis therapy naïve (n=7) (n= 6) Number of 3 (50%) 3 (43%) patients with PR *PR –Partial Response - RESIST 1.1 : At least a 30% decrease in the sum of diameters of target lesions, taking as reference the base
Slide 37: Efficacy Summary
Plinabulin+ Nivolumab +Ipilimumab in SCLC: Big Ten ITT Phase 1 Study Improvement of Overall Response Rate 46% 50% 43% 45% 40% 35% 30% 23% Efficacy Summary 25% 20% 15% 11% 10% 5% 0% Nivolumab Nivolmumab + Plinabulin + Plinabulin + Ipilimumab Nivolumab + Nivolumab + Ipilimumab Ipilimumab (CPI resistan
Slide 38: Plinabulin as a Potential Synergistic Cornerstone Agent in IO Therapy
Plinabulin as a Potential Synergistic “Cornerstone” Agent in IO Therapy Data Conclusion • High response rate to previous • Immune system re-sensitized CPI failures (43%) • Improved Anti-cancer Response • Increased antigen presentation (46% ORR vs. 12-23% CPI) simulates T cell activation • Durable re
Slide 39: Recent Goals Achieved, Near Term Milestones for Value Creation
Recent Goals Achieved, Near Term Milestones for Value Creation CIN (Target broad range of cancer and chemotherapy) ✓ Value creation in elevating SOC; Plinabulin ✓ Life cycle management Life-cycle Management 2022+ Anti-cancer I/O Combo Early Clin. Data ✓ NSCLC (with chemo): 2022 • Large and growing p
Slide 40: Corporate Highlights
BeyondSpring Corporate Highlights
Slide 41: Hengrui is the Ideal Partner for Plinabulin in Greater China
Hengrui is the Ideal Partner for Plinabulin in Greater China Exceptional synergy between plinabulin and Hengrui pipeline ➢ Hengrui is the leader in oncology product R&D and commercialization in China • Established in 1970; Listed on Shanghai Stock Exchange in 2000 (Shanghai stock exchange ticker: 60
Slide 42: Hengrui Partnership Supports Key Commercialization Goals in China
Hengrui Partnership Supports Key Commercialization Goals in China Manages commercialization risk and optimizes return on plinabulin franchise • Leverages existing infrastructure of leading oncology player • Minimizes launch investment and risk • Optimizes near-term return through performance-related
Slide 43: Hengrui and Wanchunbulin Partnership in Greater China - Key Terms
Hengrui and Wanchunbulin Partnership in Greater China - Key Terms (BeyondSpring Inc. owns 58% of Wanchunbulin) Key Synergies Allow for a Mutually Beneficial “Win-Win” Deal Hengrui: Plinabulin Rights in Greater China Terms (est. USD*) • Exclusive commercialization of all • Wanchunbulin receives $30M
Slide 44: SEED Therapeutics Subsidiary – Pipeline Potential
SEED Therapeutics Subsidiary – Pipeline Potential SEED: subsidiary pursuing "Molecular Glue" targeted protein degradation to degrade disease-causing proteins previously believed to be undruggable • $800M collaboration with Eli Lilly on three targets • Own targets (e.g., KRAS) • Structure conducive t
Slide 45: BeyondSpring: Key Highlights
BeyondSpring: Key Highlights Committed to raising the standard of care for cancer with first-in-class treatments that improve lives and Mission clinical outcomes for millions of patients in need Near-term Global Capabilities Broad Pipeline Global Market Opportunities Continuous Innovation Plinabulin
Slide 46: www.beyondspringpharma.com
www.beyondspringpharma.com 46
Slide 47: APPENDIX - CIN
* BeyondSpring APPENDIX - CIN
Slide 48: PROTECTIVE-2 Ph 3: Clinical Consequences of CIN also Reduced by Combination
PROTECTIVE-2 Ph 3: Clinical Consequences of CIN also Reduced by Combination Pegfilgrastim 6 mg Plinabulin 40 mg + Pegfilgrastim 6 mg ANC Nadir N=110 N=111 Mean nadir for FN patients 0.06 0.13 (x109 cells/L) Mean nadir for all patients 0.31 0.54 (x109 cells/L) ANC benefit of the combination improves
Slide 49: Adverse Reactions Occurring in ≥ 5% of Patients, Plinabulin + Pegfilgrastim vs. Pegfilgrastim
Adverse Reactions Occurring in ≥ 5% of Patients in the Plinabulin + Pegfilgrastim vs. Pegfilgrastim Pegfilgrastim 6 mg Plinabulin 40 mg** + Pegfilgrastim 6 mg N=132 N=127 Body System/Preferred Term All Grade Grade 3/4 All Grade Grade 3/4 Gastrointestinal disorders 22 (16.7%) 1 (0.8%) 49 (38.6%) 9 (7
Slide 50: Combination with Superior Improvement in Clinically Meaningful Endpoints
The combination with Superior Improvement in Clinically Meaningful Endpoints compared to Pegfilgrastim alone Reduction of Incidence and Reduction of Profound Improvement of Severity of FN and Neutropenia (PN) Related Hospitalization Benefits Quality of Life Clinical Endpoints Profound Neutropenia En
Slide 51: Monotherapy G-CSF Fails to Prevent Chemo Regimen Changes
Monotherapy G-CSF Fails to Prevent Chemo Regimen Changes Percent of patients with significant regimen changes mFOLFOX6 CRC Chemo regimen FOLFOX4 changes are NSCLC Cisplatin, vinorelbine unacceptably high Ovarian carboplatin, paclitaxel Patients’ experience: AC→doceltaxel • Dose reduction • Dose dela
Slide 52: Detailed Commercialization Plan
Detailed Commercialization Plan 1 2 3 Neutropenia Vulnerability Gap and Positioning Plinabulin with Activating Key accounts and Unmet Need Awareness Key Decision Makers Ensuring Broad Patient Access KOLs: • Advocacy and Expert network State of the Art Promotion Programs: • Major health care congress
BeyondSpring — Investor Presentation (September 2021) on 6ix